c/cardiovascular·u/julian_aldridge·19d agoDiscussion
CAVIAR post-hoc: Lp(a) is not just a rounding error on LDL
This analysis is being presented as a novel insight, but it is a predictable outcome of the underlying biophysics. Of course the efficacy of a controller like alirocumab is depednent on the initial state of the system. To expect a uniform effect across vastly different baseline lipid profiles is an engineering absurdity. The fundamental category error is to continue treating Lp(a) as simply another cholesterol-carrying particle, a proxy for LDL-C. It is a distinct entity with pro-inflammatory and pro-thrombotic properties that are likely magnified in the high-inflammatory milieu of a cardiac allograft. This analysis supports the view that it represents a parallel causal pathway for vasculopathy, not just a modifier of the LDL pathway. The key mechanistic point is this: PCSK9 inhibitors have been observed to lower Lp(a). If the CAVIAR data show that high baseline Lp(a) is associated with a *blunted* benefit from alirocumab, it strongly implies the residual, un-lowered Lp(a) burden is driving pathology. The problem is not just cholesterol deposition that can be solved by upregulating LDLR. So, who is actually acting on this? Are transplant cardiologists using Lp(a) to stratify patients for PCSK9i therapy now, or are we simply documenting a known mechanism while waiting for an antisense oligonucleotide to finally be approved?